<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179983</url>
  </required_header>
  <id_info>
    <org_study_id>NHSTayside</org_study_id>
    <nct_id>NCT02179983</nct_id>
  </id_info>
  <brief_title>Tayside Rehabilitation in Bronchiectasis Exacerbations (TRIBE) : a Randomized Controlled Trial</brief_title>
  <acronym>TRIBE</acronym>
  <official_title>A Randomized Controlled Trial of Pulmonary Rehabilitation After Exacerbations of Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Tayside</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary rehabilitation is well established as a treatment in COPD. After exacerbations of&#xD;
      COPD, rehabilitation is associated with reduced frequency of exacerbations and improved&#xD;
      exercise capacity. No data are available in bronchiectasis.&#xD;
&#xD;
      This study will randomly assign patients with bronchiectasis exacerbations to pulmonary&#xD;
      rehabilitation or standard care. The hypothesis is that exercise capacity will be improved by&#xD;
      pulmonary rehabilitation at 8 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Pulmonary rehabilitation is an effective treatment after exacerbations of COPD to&#xD;
      prevent future exacerbations and to improve breathlessness and quality of life. Its&#xD;
      effectiveness after exacerbations of bronchiectasis has never been demonstrated.&#xD;
&#xD;
      Aims: To determine if a 6 week course of pulmonary rehabilitation improves exercise capacity&#xD;
      at 8 weeks after exacerbation.&#xD;
&#xD;
      Study Design: Randomised controlled trial. Methods: The study will take place in NHS Tayside.&#xD;
      40 patients with a history of bronchiectasis confirmed by HRCT will be included. Patients&#xD;
      will be monitored using diary cards for exacerbations. At the onset of an exacerbation&#xD;
      patients will be treated with a standard 14 day course of antibiotic therapy and randomised&#xD;
      to one of two arms: Pulmonary rehabilitation or standard care. Patients randomised to&#xD;
      pulmonary rehabilitation will undergo a 6 week course of supervised pulmonary rehabilitation.&#xD;
      Patients will undergo study assessments (6-minute walk test, Quality of life questionnaires,&#xD;
      pulmonary function tests (FEV1, FVC, FEF 25-75), symptoms recorded by symptom diaries and&#xD;
      sputum microbiology).Assessments will be performed at the start and end of exacerbations, at&#xD;
      6-8 weeks post exacerbation (after completion of pulmonary rehabilitation in patients&#xD;
      randomised to rehabilitation) and at 12 weeks.&#xD;
&#xD;
      Outcome: The primary outcome is 6 minute walk distance at 8 week post exacerbation Expected&#xD;
      Conclusion: We will determine the effectiveness of pulmonary rehabilitation after&#xD;
      exacerbations of bronchiectasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>8 weeks post exacerbation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next exacerbation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of life</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>St Georges respiratory questionnaire COPD assessment test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>Pulmonary function tests (FEV1, FVC, FEF25-75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>Patient diary cards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum microbiology</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>Proportion of patients with positive sputum microbiology of potential pathogenic microorganisms (Haemophilus influenzae, Pseudomonas aeruginosa, Moraxella catarrhalis, enterobacteriaceae) versus patients without sputum colonisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care for exacerbation and follow-up without rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary rehabilitation</intervention_name>
    <description>6 weeks of supervised exercise and education (pulmonary rehabilitation)</description>
    <arm_group_label>Pulmonary rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary rehabilitation</intervention_name>
    <description>6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)</description>
    <arm_group_label>Pulmonary rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Bronchiectasis confirmed on High Resolution CT scan Clinical Bronchiectasis confirmed by a&#xD;
        respiratory physician. Documented exacerbation within the last year. Independently mobile -&#xD;
        i.e. able to undertake pulmonary rehabilitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent to participate&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Primary diagnosis of Chronic Obstructive Pulmonary Disease&#xD;
&#xD;
          -  Significant comorbidity that would limit the ability to undertake pulmonary&#xD;
             rehabilitation - i.e. Cerebrovascular, cardiovascular or musculoskeletal disease.&#xD;
&#xD;
          -  Cystic Fibrosis&#xD;
&#xD;
          -  Aortic aneurysm&#xD;
&#xD;
          -  Recent myocardial infarction (within previous year)or unstable angina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Chalmers, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Tayside</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Fardon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Tayside</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Centre, University of Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>exercise</keyword>
  <keyword>exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

